

# Antonio Nicolucci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5238607/publications.pdf>

Version: 2024-02-01

75  
papers

3,316  
citations

201385

27  
h-index

155451

55  
g-index

79  
all docs

79  
docs citations

79  
times ranked

4895  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 313.	3.8	329
2	Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2021, 372, m4573.	3.0	322
3	Effect of an Intensive Exercise Intervention Strategy on Modifiable Cardiovascular Risk Factors in Subjects With Type 2 Diabetes Mellitus<sub>title>>A Randomized Controlled Trial: The Italian Diabetes and Exercise Study (IDES)</sub><sub>title>></sub><alt-title>>Intensive Exercise and Modifiable CV Risk Factors</alt-title>>. <i>Archives of Internal Medicine</i> , 2010, 170, 1794.	4.3	270
4	Mobile App-Based Interventions to Support Diabetes Self-Management: A Systematic Review of Randomized Controlled Trials to Identify Functions Associated with Glycemic Efficacy. <i>JMIR MHealth and UHealth</i> , 2017, 5, e35.	1.8	220
5	Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. <i>Journal of Hypertension</i> , 2011, 29, 1802-1809.	0.3	198
6	Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). <i>Cardiovascular Diabetology</i> , 2018, 17, 150.	2.7	149
7	Diabetes Interactive Diary: A New Telemedicine System Enabling Flexible Diet and Insulin Therapy While Improving Quality of Life. <i>Diabetes Care</i> , 2010, 33, 109-115.	4.3	142
8	HbA1c Variability as an Independent Correlate of Nephropathy, but Not Retinopathy, in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2301-2310.	4.3	130
9	Effect of a Behavioral Intervention Strategy on Sustained Change in Physical Activity and Sedentary Behavior in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 880.	3.8	89
10	Changes in Physical Fitness Predict Improvements in Modifiable Cardiovascular Risk Factors Independently of Body Weight Loss in Subjects With Type 2 Diabetes Participating in the Italian Diabetes and Exercise Study (IDES). <i>Diabetes Care</i> , 2012, 35, 1347-1354.	4.3	81
11	Impact of the "Diabetes Interactive Diary" Telemedicine System on Metabolic Control, Risk of Hypoglycemia, and Quality of Life: A Randomized Clinical Trial in Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 670-679.	2.4	80
12	Variability in <math>HbA_{1c}</math>, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1570-1578.	2.2	70
13	Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency And Cardiovascular Events (RIACE) study. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3950-3954.	0.4	65
14	Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2019, 151, 20-32.	1.1	63
15	Baseline Quality-of-Care Data From a Quality-Improvement Program Implemented by a Network of Diabetes Outpatient Clinics. <i>Diabetes Care</i> , 2008, 31, 2166-2168.	4.3	61
16	Quality of Diabetes Care Predicts the Development of Cardiovascular Events: Results of the AMD-QUASAR Study. <i>Diabetes Care</i> , 2011, 34, 347-352.	4.3	53
17	The Italian Diabetes and Exercise Study (IDES): Design and methods for a prospective Italian multicentre trial of intensive lifestyle intervention in people with type 2 diabetes and the metabolic syndrome. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 585-595.	1.1	50
18	Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1188-1196.	1.2	46

#	ARTICLE	IF	CITATIONS
19	Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1885-1893.	2.2	45
20	Interplay among patient empowerment and clinical and person-centered outcomes in type 2 diabetes. The BENCH-D study. <i>Patient Education and Counseling</i> , 2015, 98, 1142-1149.	1.0	43
21	Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: retrospective data for 10%256 individuals from the United Kingdom and Germany. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 389-399.	2.2	38
22	Quality of diabetes care predicts the development of cardiovascular events: Results of the QuED study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 57-65.	1.1	37
23	Trends over 8 years in quality of diabetes care: results of the AMD Annals continuous quality improvement initiative. <i>Acta Diabetologica</i> , 2015, 52, 557-571.	1.2	36
24	Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2474-2485.	2.2	36
25	Gender-Disparities in Adults with Type 1 Diabetes: More Than a Quality of Care Issue. A Cross-Sectional Observational Study from the AMD Annals Initiative. <i>PLoS ONE</i> , 2016, 11, e0162960.	1.1	31
26	The Drug Derived Complexity Index (DDCI) Predicts Mortality, Unplanned Hospitalization and Hospital Readmissions at the Population Level. <i>PLoS ONE</i> , 2016, 11, e0149203.	1.1	30
27	Level and correlates of physical activity and sedentary behavior in patients with type 2 diabetes: A cross-sectional analysis of the Italian Diabetes and Exercise Study_2. <i>PLoS ONE</i> , 2017, 12, e0173337.	1.1	29
28	The adolescent with obesity: what perspectives for treatment?. <i>Italian Journal of Pediatrics</i> , 2022, 48, 9.	1.0	29
29	Improvement of Quality of Life With Supervised Exercise Training in Subjects With Type 2 Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2011, 171, 1951.	4.3	28
30	Overall Quality of Care Predicts the Variability of Key Risk Factors for Complications in Type 2 Diabetes: An Observational, Longitudinal Retrospective Study. <i>Diabetes Care</i> , 2019, 42, 514-519.	4.3	28
31	Effect of a Behavioral Intervention Strategy for Adoption and Maintenance of a Physically Active Lifestyle: The Italian Diabetes and Exercise Study 2 (IDES_2). <i>Diabetes Care</i> , 2017, 40, 1444-1452.	4.3	26
32	Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes. <i>Diabetes Therapy</i> , 2020, 11, 573-584.	1.2	25
33	Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study. <i>Cardiovascular Diabetology</i> , 2021, 20, 59.	2.7	23
34	Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001481.	1.2	22
35	Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 66-78.	2.2	20
36	Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1484-1495.	2.2	20

#	ARTICLE	IF	CITATIONS
37	Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. <i>Advances in Therapy</i> , 2018, 35, 243-253.	1.3	19
38	Development and validation of a questionnaire evaluating the impact of hepatitis B immune globulin prophylaxis on the quality of life of liver transplant recipients. <i>Liver Transplantation</i> , 2012, 18, 332-339.	1.3	17
39	Obesity in Germany and Italy: prevalence, comorbidities, and associations with patient outcomes. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 457-475.	0.7	17
40	Real-world use of self-monitoring of blood glucose in people with type 2 diabetes: an urgent need for improvement. <i>Acta Diabetologica</i> , 2018, 55, 1059-1066.	1.2	16
41	Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study. <i>American Heart Journal</i> , 2022, 243, 232-239.	1.2	14
42	The Italian Diabetes and Exercise Study 2 (IDES-2): a long-term behavioral intervention for adoption and maintenance of a physically active lifestyle. <i>Trials</i> , 2015, 16, 569.	0.7	12
43	Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 707-715.	1.1	11
44	Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice. <i>Advances in Therapy</i> , 2019, 36, 2895-2909.	1.3	11
45	Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study. <i>Diabetes Therapy</i> , 2021, 12, 509-525.	1.2	11
46	Is it time to consider depression as a major complication of type 2 diabetes? Evidence from a large population-based cohort study. <i>Acta Diabetologica</i> , 2022, 59, 95-104.	1.2	9
47	<p>Penetration force and cannula sliding profiles of different pen needles: the PICASSO study</p>. <i>Medical Devices: Evidence and Research</i> , 2019, Volume 12, 311-317.	0.4	8
48	Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1956-1960.	2.2	8
49	Incidence of severe hypoglycemia and possible associated factors in pediatric patients with type 1 diabetes mellitus in the real-life, post-CCT setting: a systematic review. <i>Pediatric Diabetes</i> , 2019, 20, 678-692.	1.2	7
50	Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1823-1833.	2.2	7
51	Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2587-2595.	1.1	7
52	A multistep approach for the stratification of the risk of severe hypoglycemia in patients with type 2 diabetes. <i>Minerva Endocrinology</i> , 2018, 43, 501-510.	0.6	7
53	Urban diabetes: the case of the metropolitan area of Rome. <i>Acta Biomedica</i> , 2019, 90, 209-214.	0.2	7
54	Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study. <i>Frontiers in Endocrinology</i> , 2022, 13, 831676.	1.5	7

#	ARTICLE	IF	CITATIONS
55	Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the <scp>GetGoal</scp> programme. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 248-256.	2.2	6
56	Independent association of atherogenic dyslipidaemia with all-cause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study. <i>Cardiovascular Diabetology</i> , 2021, 20, 28.	2.7	6
57	Effectiveness of <i>Ascophyllum nodosum</i> and <i>Fucus vesiculosus</i> on Metabolic Syndrome Components: A Real-World, Observational Study. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-8.	1.0	6
58	Temporal trends in intensification of glucose-lowering therapy for type 2 diabetes in Italy: Data from the AMD Annals initiative and their impact on clinical inertia. <i>Diabetes Research and Clinical Practice</i> , 2021, 181, 109096.	1.1	6
59	Effect of a Behavioural Intervention for Adoption and Maintenance of a Physically Active Lifestyle on Psychological Well-Being and Quality of Life in Patients with Type 2 Diabetes: The IDES_2 Randomized Clinical Trial. <i>Sports Medicine</i> , 2022, 52, 643-654.	3.1	5
60	Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001585.	1.2	4
61	Perceived Benefits, Barriers, and Facilitators of a Digital Patient-Reported Outcomes Tool for Routine Diabetes Care: Protocol for a National, Multicenter, Mixed Methods Implementation Study. <i>JMIR Research Protocols</i> , 2021, 10, e28391.	0.5	4
62	Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109218.	1.1	4
63	Efficacy, safety and acceptability of the new pen needle 34G x 3.5mm: a crossover randomized non-inferiority trial; AGO 02 study. <i>Current Medical Research and Opinion</i> , 2018, 34, 1699-1704.	0.9	3
64	Clinical Outcomes of Switching to Insulin Glargine 300 U/ml from Other Basal Insulins in People with Type 2 Diabetes in Italy: A Real-World Study. <i>Diabetes Therapy</i> , 2020, 11, 2283-2298.	1.2	3
65	Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 99.	1.0	3
66	Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: Results from the DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108947.	1.1	3
67	Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2021, 180, 108974.	1.1	3
68	Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108077.	1.2	3
69	Clinical profiles and quality of care of adults with type 1 diabetes according to their cardiovascular Risk: A Multicenter, Observational, retrospective study. <i>Diabetes Research and Clinical Practice</i> , 2021, 182, 109131.	1.1	3
70	Association between On-Treatment Haemoglobin A1c and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 246.	1.0	2
71	Glycated Albumin for Glycemic Control in T2DM Population: A Multi-Dimensional Evaluation. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 453-464.	0.7	2
72	Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1st generation basal insulins. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, , .	1.1	1

#	ARTICLE	IF	CITATIONS
73	Accuracy of the Standard GlucoNavii Mentor in Blood Glucose Monitoring According to International Organization for Standardization 15197:2013 Criteria. JMIR Diabetes, 2022, 7, e20774.	0.9	0
74	Compatibility of PiC Insupen Needles with a Broad Range of Pens for the Injection of Subcutaneously Administered Drugs for Diabetes. Medical Devices: Evidence and Research, 2022, Volume 15, 71-77.	0.4	0
75	Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global <sc>DISCOVER</sc> study. Diabetes, Obesity and Metabolism, 2022, 24, 1734-1740.	2.2	0